 The Hindu |
Vertex asks US panel to endorse hepatitis drug
Reuters SILVER SPRING, Md., April 28 (Reuters) – Vertex Pharmaceuticals Inc (VRTX.O) urged US advisers on Thursday to back its experimental drug that cured nearly 80 percent of newly treated patients with hepatitis C, a virus that can destroy … Vertex offers a blockbuster case for telaprevir FDA panel recommends Merck hepatitis C drug ((Morning Read) FDA Panel Meets Today on Vertex HepC Drug |
View full post on Health – Google News
